Table 6.

Incidence of endometrial hyperplasia after treatment of unopposed E2 vs E2/NETA after one year of therapy

Medication	E2 50 μg	E2 50 μg/NETA 140 μg	E2 50 μg/NETA 200 μg	E2 50 μg/NETA 400 μg
Endometrial hyperplasia	37.9%	0.8%*	1%*	1.1%* *p < 0.01

^*p < 0.01